People

Peg Brivanlou specializes in patent prosecution, client counseling, due diligence and patent litigation. As a Partner in our Intellectual Property, Patent, Trademark and Copyright Litigation practice, Peg represents clients in the biotechnology and pharmaceutical industries, and investment funds in a variety of intellectual property matters.

With a focus on biologics and small molecule therapeutics, Peg counsels clients regarding immunotherapeutics, cell-based assays and therapies, genomics, bioinformatics, vaccines and small molecule pharmaceuticals. She is experienced in developing patent portfolios, particularly relating to biologics, antibody therapeutics and diagnostics. She also conducts patent invalidity, freedom-to-operate analyses and pre-litigation investigations, including for pre-Hatch-Waxman litigation.

In addition, Peg represents clients on the intellectual property aspects of a wide range of transactions, from technology transfer and out-licensing to multi-million-dollar asset purchases and financings. She conducts due diligence, and negotiates licensing and purchase agreements as well as disclosure documents in connection with public and private financings.

Presenting to conferences and in-house counsel, Peg is a frequent speaker on a variety of patent issues.

Full Bio

Credentials

J.D., Harvard University, cum laude

Ph.D., University of California, Berkeley

A.B., Cornell University, magna cum laude

New York

U.S. Patent and Trademark Office

New York Intellectual Property Law Association

New York State Bar Association

French

Matters

Primary intellectual property counsel to a private investment fund in connection with significant royalty stream acquisitions and financings.

Represents a private biotechnology company in developing patent portfolio relating to immunotherapeutics.

Represents a major pharmaceutical company in patent prosecution and counseling relating to small molecule pharmaceuticals, including approved products and products in late stage clinical trials, for cardiovascular indications.

See more
Icon close

Close

Matters

Primary intellectual property counsel to a private investment fund in connection with significant royalty stream acquisitions and financings.

Represents a private biotechnology company in developing patent portfolio relating to immunotherapeutics.

Represents a major pharmaceutical company in patent prosecution and counseling relating to small molecule pharmaceuticals, including approved products and products in late stage clinical trials, for cardiovascular indications.

Represents a foreign pharmaceutical firm in patent prosecution and counseling relating to RNAi therapeutics.

Represented a major pharmaceutical company and private biotechnology companies in administrative and court challenges against the USPTO relating to patent term adjustment calculations.

Insights

Article · Source: Law360

June 15, 2017
High Court's Superficial Analysis In Biosimilars Ruling

Client Alert

June 13, 2017
The Age of Competition

Article · Source: Intellectual Property Magazine

June 12, 2017
Clarity From Chaos

View all

Matters

Primary intellectual property counsel to a private investment fund in connection with significant royalty stream acquisitions and financings.

Represents a private biotechnology company in developing patent portfolio relating to immunotherapeutics.

Represents a major pharmaceutical company in patent prosecution and counseling relating to small molecule pharmaceuticals, including approved products and products in late stage clinical trials, for cardiovascular indications.

See more
Icon close

Close

Matters

Primary intellectual property counsel to a private investment fund in connection with significant royalty stream acquisitions and financings.

Represents a private biotechnology company in developing patent portfolio relating to immunotherapeutics.

Represents a major pharmaceutical company in patent prosecution and counseling relating to small molecule pharmaceuticals, including approved products and products in late stage clinical trials, for cardiovascular indications.

Represents a foreign pharmaceutical firm in patent prosecution and counseling relating to RNAi therapeutics.

Represented a major pharmaceutical company and private biotechnology companies in administrative and court challenges against the USPTO relating to patent term adjustment calculations.

Insights

Article · Source: Law360

June 15, 2017
High Court's Superficial Analysis In Biosimilars Ruling

Client Alert

June 13, 2017
The Age of Competition

Article · Source: Intellectual Property Magazine

June 12, 2017
Clarity From Chaos

View all

Credentials

J.D., Harvard University, cum laude

Ph.D., University of California, Berkeley

A.B., Cornell University, magna cum laude

New York

U.S. Patent and Trademark Office

New York Intellectual Property Law Association

New York State Bar Association

French